CDK4/6抑制剂的联合治疗模式

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers

细胞周期素依赖激酶(CDKs)抑制剂联合内分泌治疗已经用于晚期乳腺癌的治疗。除了内分泌治疗,CDK4/6抑制剂还可以联合表皮生长因子受体(EGFR)抑制剂、磷脂酰肌醇-3激酶(PI3K)/哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂、化学治疗、免疫治疗、分子靶向治疗和其他治疗。联合治疗模式克服了CDK4/6抑制剂的耐药并提高了临床疗效,开启了肿瘤精准治疗的一扇新窗口。

Cyclin-dependent kinases(CDKs)inhibitors have been approved in the combination with hormonebased therapy for advanced breast cancer.In addition to endocrine therapy,the combinations of CDK4/6 inhibitors with epidermal growth factor receptor(EGFR)inhibitors,phosphoinositide 3-kinase(PI3K)/mammalian target of rapamycin(mTOR)inhibitors,chemotherapy,immune therapy,molecular targeted agents and the other therapeutics could overcome its resistance and improve clinical benefits.CDK4/6 inhibitorsbased combinational therapeutics provides a promising window for human cancer treatment.